Allogene Therapeutics announced that it has received a $15 million grant from the California Institute for Regenerative Medicine, CIRM, to support the clinical development of ALLO-316, an AlloCAR T investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma, RCC. The grant will support the ongoing Phase 1 TRAVERSE trial which assesses safety, tolerability and preliminary efficacy of ALLO-316 in advanced RCC that has progressed despite standard therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- IO Biotech appoints Shamsaei as SVP, Commercial Development
- Allogene Therapeutics Announces Q2 Investor Conference Participation
- Allogene Therapeutics management to meet with Truist
- Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call
